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Background: The development of highly vascularized and inflammatory periprosthetic   tissue 
characterizes the progress of aseptic loosening, a major complication of joint arthroplasty. 
Vascular endothelial growth factor (VEGF) is an important cell signaling protein involved in 
angiogenesis. The purpose of this study was to investigate whether R2/Fc (a VEGF neutralizing 
antibody) and SU5416 (a VEGF receptor II [Flk-1] inhibitor) could ameliorate particle-induced 
inflammatory osteolysis in a mouse model.
Methods: Ultrahigh molecular weight polyethylene (UHMWPE) particles were introduced 
into established air pouches in BALB/c mice, followed by implantation of calvaria bone from 
syngeneic littermates. Drug treatment was started 2 weeks after bone implantation, and mice 
without drug treatment were included as controls. Pouch tissues were harvested 4 weeks after 
bone implantation for molecular and histological analysis, and implanted bone degradation was 
analyzed by microcomputed tomography.
Results: Exposure to UHMWPE particles induced inflammatory osteolysis, which was 
associated with increased expression of VEGF/Flt-1 proteins. Treatment with R2/Fc significantly 
improved UHMWPE particle-induced inflammatory osteolysis, and reduced the expression of 
VEGF/Flt-1 proteins. However, SU5416 treatment showed no effect on UHMWPE particle-
induced inflammatory osteolysis.
Conclusion: Our findings indicate that VEGF signaling exerts a regulatory effect on the 
  development of UHMWPE-induced inflammatory osteolysis, through its unique Flt-1, rather than 
Flk-1, receptor located on monocyte/macrophage cell lineages. These data provide a biological 
rationale for a VEGF/Flt-1-targeted treatment strategy, especially during the early stages of the 
wear debris-induced inflammatory response.
Keywords: vascular endothelial growth factor, FLT-1, osteolysis, osteoclastogenesis, R2/Fc, 
SU5416, animal model, wear debris
Introduction
It is estimated that more than 500,000 total joint arthroplasties are performed in the 
US annually. Aseptic loosening due to wear debris-induced osteolysis is the most 
common cause of implant failure.1,2 Aseptic loosening is characterized by the forma-
tion of a chronic inflammatory response to wear debris from the implant, leading 
to bone resorption (osteolysis) and loss of fixation.3 The periprosthetic tissue at the 
bone-implant interface shows a high degree of vascularization.4 A number of factors 
contribute to angiogenesis, and the major signaling protein, vascular endothelial Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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growth factor (VEGF) is produced by multiple cell types, 
including macrophages and osteoblasts.5,6 VEGF exerts 
its biological activity by binding to two receptors, VEGF 
receptor-1 (VEGFR-1; Flt-1) and VEGFR-2 (Flk-1/KDR).7 
VEGF is actively involved in the process of inflammation,8 
osteoclastogenesis,9,10 and bone resorption.10 However, the 
role of VEGF in wear debris-induced inflammatory osteolysis 
has not been well determined.
VEGF R2/Fc chimera is a 110 kDa peptide containing the 
extracellular domain of a VEGF receptor linked to the heavy 
chain of the IgG molecule, which binds and inactivates free 
VEGF. Efforts toward the discovery of receptor tyrosine kinase 
inhibitors with specific activity against VEGF receptors have 
led to the synthesis and characterization of a number of novel 
compounds. One of these SU5416,11 a cell-permeable indoli-
none compound that acts as a selective adenosine triphosphate 
(ATP)-competitive inhibitor of VEGF-R2 (KDR/Flk-1), with 
slightly weaker inhibition of VEGF-R1 (Flt-1). However, it 
appears to be specific for VEGF receptors because it has no 
effect on other kinases, such as the epidermal growth factor 
receptor, in concentrations up to 10 µM. Using a well estab-
lished mouse osteolysis model,12,13 we report that exposure 
to ultrahigh-molecular-weight polyethylene (UHMWPE) 
particles increased VEGF expression at both the mRNA 
and protein levels in pouch tissues, and increased VEGF 
gene expression is closely associated with pouch tissue 
inflammation status, suggesting that VEGF has a role in the 
regulation of implant wear-induced tissue inflammation and 
osteoclastogenesis.14 Furthermore, we also found that VEGF 
inhibitor treatment significantly prevented the development 
of UHMWPE particle-induced inflammation and osteoclastic 
bone resorption using this mouse model.13 The aim of this 
study was to investigate the therapeutic response of either 
VEGF R2/Fc or SU5416 in a mouse model of UHMWPE 
particle-induced inflammatory osteolysis.
Materials and methods
Materials
Female BALB/c mice (aged 8–10 weeks) were pur-
chased from Jackson Laboratory (Bar Harbor, ME) and 
quarantined within Wayne State University facility prior 
to experimentation. Recombinant human VEGF 165 
(293-VE), a 42 kDa peptide with 97% homology to rabbit 
and mouse VEGF, was purchased from R & D Systems 
(Minneapolis, MN). VEGF R2/Fc was purchased from 
R & D Systems. SU5416 was purchased from Calbiochem 
(San Diego, CA). Rabbit-anti-VEGF-A (sc-152) and 
goat polyclonal antibodies against interleukin (IL)-1β, 
tumor necrosis factor-α (TNF-α), RANKL, and CD68 
were purchased from Santa Cruz Biotechnology (Santa 
Cruz, CA).
Ultra high molecular weight polyethylene 
particles
UHMWPE15 particles were gifted by John Cuckler from 
the University of Alabama, Birmingham, AL. Scanning 
electron microscopy analysis demonstrated that 90% of 
the UHMWPE particles were less than 5.5 µm in diameter, 
with a mean size of 2.6 µm, and diameters ranging from less 
than 0.6 µm to 21 µm (standard deviation [SD] 2.4 µm). 
UHMWPE particles were washed in 70% ethanol solution 
briefly and resuspended in sterile phosphate-buffered saline 
for injection. The particle suspension was determined to be 
endotoxin-free by the Limulus assay (Endosafe, Charles 
Rivers, Charlestown, SC).
Mouse osteolysis model and drug 
treatment
Institutional approval was obtained for all animal proce-
dures. The use of the bone-implanted inflammatory air 
pouch as a model of debris-induced osteolysis has been 
described previously.12 Air pouches were established in 
female BALB/c mice as described elsewhere.15 Six days 
later, mice with established air pouches were anesthetized 
by intraperitoneal injection of pentobarbital 50 mg/kg 
(Fisher Scientific, Pittsburgh, PA). A 0.5 cm incision 
overlying the pouch was made, and a section of calvaria 
bone (approximately 0.4 × 0.25 cm) from a genetically 
identical donor mouse was inserted into the pouch. The 
pouch layers and the skin incision were then closed 
using 4-0 Prolene sutures. On the following day, pouches 
were injected with 0.5 mL saline containing either 1% 
UHMWPE or saline alone (control). Seven days after 
bone implantation, pouches were rechallenged with either 
0.5 mL of UHMWPE particles (1%) to maintain persis-
tent inflammation or with 0.5 mL of saline for the control 
groups. Fourteen days after particle implantation, while 
UHMWPE particles induced inflammatory osteolysis, 
0.9% saline was injected intraperitoneally in the absence 
(untreated) or presence of recombinant human VEGF 165 
5 µg/kg/day, VEGF R2/Fc chimera 5 µg/kg/day, or SU5416 
20 mg/kg/day. Drug treatment was continued for 14 days 
until the mice were sacrificed. The pouches injected with 
saline alone were included as a control. Each experimental Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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group included eight mice. The experimental design and 
grouping are outlined in Table 1. Mice were sacrificed in 
a carbon dioxide chamber at 14 days after drug treatment. 
The pouch membranes containing implanted bone were 
harvested for morphological analysis.
histological evaluation and image analysis
The histological parameters of inflammatory osteolysis 
were measured using techniques described elsewhere.15 
Tissue samples were fixed in 10% formalin, followed by 
decalcification in 10% ethylenediamine tetra-acetic acid, 
and were paraffin-embedded. Tissue sections (6 µm) were 
stained with hematoxylin and eosin to evaluate pouch 
membrane inflammation and implant bone erosion. Four 
separate sections per specimen were evaluated in a blinded 
fashion. Digital images were acquired using a Zeiss light 
microscope equipped with a Toshiba CCD, and these 
images were analyzed using the Image-Pro software 
package (Media Cybernetics, Silver Spring, MD). Pouch 
membrane thickness was determined at six points on each 
section, with an even distribution of measurement on the 
proximal side, distal side, and transition curve of the pouch. 
The total number of cells (based upon nucleus count) was 
analyzed as described previously.15
evaluation of osteoclastogenesis
Osteoclast-like cells were identified by tartrate-resistant acid 
phosphatase (TRAP, EC3.1.3.2) staining in paraffin tissue 
sections using a commercial kit (Sigma, St. Louis, MO), as 
described previously.16 The presence of dark purple-staining 
granules in the cytoplasm was considered to be the specific 
criterion for TRAP+ cells. Positive TRAP localization was 
quantified by pixel area count and reported as a percentage 
of the total implanted bone area in the pouch tissue using 
the Image-Pro software package (Image-Pro Plus, Media 
Cybernetics).
immunohistological stains for VegF, FLT-1, 
IL-1, TNF, CD 68, and RANKL
An immunohistochemical technique was performed in tissue 
paraffin sections. Briefly, tissue sections were deparaffinized 
and blocked with 1.5% normal goat serum. Rabbit or goat 
polyclonal antimouse VEGF, FLT-1, IL-1, TNF, CD68, and 
RANKL (Santa Cruz Inc) antibodies at a concentration of 
2 µg/mL were applied to sections and incubated overnight in 
a moisturized chamber at 4°C. Biotin-conjugated secondary 
antibody (goat antirabbit IgG) was incubated for 30 minutes 
after extensive washing. Avidin biotin enzyme reagent 
was then applied onto sections for 30 minutes. The color 
was developed by adding 3.3′-diaminobezidine tetrahydro-
chloride. In negative control sections, the primary antibody 
was replaced with 1.5% normal goat serum. Digital images 
of representative fields of view were captured and analyzed 
using the Image-Pro software package. The level of protein 
expression and localization were evaluated in six different 
fields and expressed as pixel density. Computerized image 
analysis was used to analyze stained sections to obtain the 
percentage of cells positive to the target protein. Using a 
400× microscope objective, eight randomly selected fields 
were analyzed for each section. Reproducibility of multiple 
sections from the same site was checked through the analysis 
of duplicates in a blind manner.
Determination of osteolysis
Mice were scanned on the day of bone implantation and four 
weeks after bone implantation (immediately before termi-
nation) using an RS-9 In Vivo MicroCT Scanner (General 
Electric Systems, London, Canada). The scan was performed 
at a resolution of 0.093 mm (cubic voxel length) using the 
manufacturer’s defined settings. After data acquisition, 
two-dimensional projection data were reconstructed into 
three-dimensional volumes, which were then reoriented in 
the appropriate dimensions to place the data sets in consistent 
orientation for image analysis. Erosion surface as a fraction 
of total bone surface was determined. Bone density of the 
calvaria was further analyzed with the proprietary micro-
computed tomography (micro CT) software.
statistical analysis
Mice were randomly assigned to three experimental groups 
with eight mice in each group. Statistical analysis among 
groups was performed by the analysis of variance test with the 
Schafer formula for post hoc multiple comparisons, using the 
SPSS software package (version 7.5; SPSS Inc, Chicago, IL). 
Table 1 Mice groups and treatment protocol
Group n Treatment
1 8 PBs (control)
2 8 UhMWPe (0.5 mg per pouch)
3 8 UhMWPe + VegF (5 µg/kg/day, intraperitoneal  
injection daily)
4 8 UhMWPe + VegF R2/Fc chimera protein  
(5 µg/kg/day, intraperitoneal injection daily)
5 8 UhMWPe + SU 5416 (20 mg/kg/day, intraperitoneal 
injection daily)
Abbreviations: PBs, phosphate-buffered saline; VegF, vascular endothelial growth 
factor; UhMWPe, ultrahigh-molecular-weight polyethylene.Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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Data were expressed as mean ± standard error of the mean. 
A P value of less than 0.05 was considered significant.
Results
Animal health
The mice used in this study tolerated both the surgery and the 
drug treatments well. No mice were excluded from this study 
due to weight loss, drug toxicity, or pouch infection, as deter-
mined by clinical observation and histological analysis.
Therapeutic effects of drugs on 
UHMWPE-induced tissue inflammation
To investigate the potential therapeutic effects of VEGF 
inhibitors on UHMWPE particle-induced inflammation, drug 
treatment was started two weeks after bone implantation, 
when UHMWPE particle stimulation had induced significant 
tissue inflammation and bone damage. As shown in Figure 1, 
image analysis of tissue sections stained with hematoxylin 
and eosin showed that UHMWPE particle-induced tissue 
inflammatory responses were characterized by increased 
cellular infiltration and membrane proliferation, compared 
with saline controls. It was observed that in mice chal-
lenged with UMHWPE particles, VEGF treatment slightly 
increased cellular infiltration and membrane proliferation 
as compared with untreated mice, although this increase 
did not reach statistical significance. Quantitative image 
analysis, as shown in Table 2, revealed that UHMWPE 
particles significantly increased pouch membrane thickness 
and the number of infiltrating cells as compared with saline-
injected controls. Treatment with F2/Rc protein significantly 
decreased UHMWPE particle-induced membrane thickness 
and cellular infiltration (P , 0.05). However, treatment with 
SU5416 showed no therapeutic effects.
The aggregation of macrophages in response to UHMWPE 
stimulation was analyzed by immunostaining of CD68, a mac-
rophage cell surface marker. As shown in Figure 1 and Table 2, 
CD68+ cells were significantly increased in response to UHM-
WPE particle stimulation, and were especially concentrated 
in areas of particle accumulation. VEGF treatment resulted 
in a slight increase of CD68+ cells in UHMWPE-containing 
pouch tissues. F2/Rc treatment reduced the number of CD68+ 
cells in the infiltrate, whereas SU5416 treatment had no effects 
on the aggregation of CD68+ cells in pouch tissues. These 
data indicate that UHMWPE-induced inflammatory cellular 
infiltration was mainly composed of macrophages, and the 
therapeutic effects of F2/Rc on UHMWPE particle-induced 
PBS UHMWPE UHMWPE + VEGF UHMWPE + SU5416 UHMWPE + R2/Fc
H&E
CD68
TNFα
IL-1β
Figure 1 Therapeutic effects of VEGF inhibitors on UHMWPE particles- induced tissue inflammation. Representative tissues histology of hematoxylin and eosin (H&E) 
stain and immunohistochemical stains of CD68, IL-1b and TNFa in mice pouch membranes. (Original magnification × 200). B, Implanted bone; M, pouch membrane. Positive 
staining was indicated by arrowhead, and UhMWPe particle deposit spot was indicated by hollow arrowhead. Data of quantitative image analysis was shown in Table 2
Abbreviations: RAnKL, Receptor activator of nuclear factor kappa B ligand; TRAP, tartrate-resistant acid phosphatase; VegF, vascular endothelial growth Factor; PBs, 
phosphate-buffered saline; UhMWPe, ultra high-molecular weight polyethylene.Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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inflammation was mainly through reduction of inflammatory 
macrophage recruitment.
Particle-induced tissue inflammation was invariably 
accompanied by local accumulation of proinflammatory 
cytokines, such as IL-1β and TNFα. Ιmmunohistochemical 
study showed that exposure to UHMWPE particles signifi-
cantly increased both IL-1β and TNFα protein staining in the 
pouch tissue (Figure 1) compared with controls. As expected, 
F2/Rc treatment significantly reduced both IL-1β and TNFα 
protein expression, while SU5416 treatment demonstrated 
little effect on cytokine production. Taken together, these data 
verified that F2/Rc treatment reduced UHMWPE particle-
induced inflammatory cytokine production and significantly 
ameliorated tissue inflammatory morphology. Pouch tissue 
inflammation, assessed by the production of IL-1β and TNFα 
in tissues of F2/Rc-treated mice, was significantly lower than 
in the tissues of untreated mice. However, no significant dif-
ference in production of these cytokines was found between 
mice with and without VEGF treatment in the presence 
of UHMWPE particle stimulation. Furthermore, SU5416 
treatment showed no therapeutic effects in improving pouch 
membrane inflammation.
Therapeutic effects of drugs on 
UhMWPe-induced VegF and Flt-1 
protein production
Immunostaining was used to measure VEGF and Flt-1 protein 
expression and location in pouch membranes. As shown in 
Figure 2A, UHMWPE particles induced strong VEGF stain-
ing, especially in the UHMWPE deposit foci surrounded by 
the aggregation of inflammatory cells that were mainly com-
posed of macrophages as previously described.14 R2/Fc treat-
ment resulted in a significant reduction of VEGF staining as 
compared with untreated mice. SU5416 treatment showed no 
effects on expression of VEGF protein. As shown in   Figure 2B, 
R2/Fc treatment significantly reduced the percentage of 
VEGF+-stained cells (P , 0.05), suggesting that UHMWPE-
induced VEGF expression was efficiently suppressed by R2/Fc 
treatment. Flt-1 staining was significantly increased by UHM-
WPE particle stimulation, as compared with control pouches 
which had received phosphate-buffered saline injections. R2/
Fc treatment significantly reduced the staining intensity of 
Flt-1 protein, but SU5416 treatment showed no change of 
Flt-1 staining intensity, as shown in Figure 2B.
Therapeutic effects of drugs on 
UhMWPe-induced osteoclastic  
bone resorption
Enhanced osteoclastogenesis has been recognized as a 
hallmark of various forms of osteoporosis, including the bone 
loss that occurs in aseptic loosening.17 RANKL/RANK sig-
naling is essential for the development of osteoclastogenesis. 
As depicted in Figure 3, the results of immunohistochemistry 
showed increased RANKL staining in UHMWPE-containing 
pouches, compared with that seen in phosphate-buffered 
saline controls. RANKL staining was predominantly found 
at the interface between pouch membrane and implanted 
bones, and in the cytoplasm of cells present within aggregates 
of inflammatory cells. As seen in Figure 3, R2/Fc treatment 
significantly reduced RANKL staining, while SU5416 treat-
ment showed no significant difference when compared with 
untreated mice (Figure 3B).
Histochemical TRAP staining was used to measure 
the number of osteoclasts in pouch tissue. Figure 3 illus-
trates discrete foci of TRAP+ cells at the interface between 
implanted calvaria and pouch membrane in pouches with 
phosphate-buffered saline injection. The bone morphology 
remained intact, and no resorption lacunae were observed. 
Intense TRAP staining was observed in pouches stimulated 
with UHMWPE, and TRAP+ cells extended into adjoining 
areas. Regions where TRAP+ cells localized were often pit-
ted, suggesting active osteoclastic bone resorption. R2/Fc 
treatment caused a significant reduction in the number of 
TRAP+ cells, and the bone resorption lacunae were remark-
ably reduced (P , 0.05). However, SU5416 treatment did not 
affect UHMWPE particle-induced increase of TRAP+ cells. 
Table 2 Quantitative assessment of the pouch membrane histology profiles by Image-Pro software analysis. Measurement of total cell 
counts in pouch tissues.
PBS UHMWPE UHMWPE + VEGF UHMWPE + R2/Fc UHMWPE + SU5416
Membrane thickness (mm)  0.015 ± 0.003 0.042 ± 0.009* 0.046 ± 0.011* 0.015 ± 0.009** 0.043 ± 0.014*
Cellular infiltration (mm2) 3590 ± 863 8331 ± 1123* 8680 ± 811* 4406 ± 951** 7496 ± 480*
CD68 positive-stained cells (%) 7.5 ± 5.2 25 ± 7.5* 22.5 ± 6.8* 13.8 ± 2.8** 25 ± 3.3*
TnFα positive-stained cells (%) 5 ± 2.9 20 ± 5.7* 19 ± 4.0* 6.6 ± 3.3** 21 ± 3.3*
iL-1β positive-stained cells (%) 8.3 ± 3.0 23.3 ± 6.8* 20 ± 6.1* 13 ± 2.8** 22 ± 3.3*
* p<0.05, vs. PBS; **p<0.05, vs. UHMWPE, UHMWPE+VEGF, and UHMWPE+SU5416. 
Abbreviations: TnF, tumor necrosis factor; iL, interleukin; PBs, phosphate-buffered saline; VegF, vascular endothelial growth factor; UhMWPe, ultrahigh-molecular-
weight polyethylene.Journal of Inflammation Research 2011:4 submit your manuscript | www.dovepress.com
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We also observed that VEGF treatment slightly increased 
TRAP+ cells in pouches with or without UHMWPE particle 
stimulation, suggesting that VEGF may have a regulatory 
role in the development of osteoclastogenesis.
Consistent with the histological profiles, UHMWPE particle 
stimulation dramatically increased the implanted bone degrada-
tion in comparison with saline controls. As shown in Figure 4A, 
the micro CT imaging analysis showed a significant alteration 
of plateau surface contour in pouches with UHMWPE particle 
stimulation, as compared with the control pouches, suggest-
ing progressive implanted bone degradation. R2/Fc treatment 
dramatically lessened bone degradation caused by UHMWPE 
particles, while SU5416 treatment did not show therapeutic 
effect on implanted bone reservation. The effects of R2/Fc 
treatment were further confirmed by quantitative bone mineral 
density measurement (P , 0.05). In summary, the data indicate 
that R2/Fc treatment has a therapeutic effect by interfering with 
UHMWPE particle-induced inflammatory osteolysis.
Discussion
This study revealed that R2/Fc protein treatment signifi-
cantly inhibits UHMWPE particle-induced pouch tissue 
  inflammation, tissue RANKL production, and TRAP+ cell 
formation, thus improving established UHMWPE particle-
induced inflammatory osteolysis in a mouse model. R2/
Fc chimera protein binds and inactivates circulating VEGF 
through its VEGF receptor domain, without triggering VEGF 
signaling. However, SU5416 (a specific Flk-1 inhibitor) treat-
ment demonstrates no effect on UHMWPE particle-induced 
inflammatory osteolysis. A proangiogenic status4 in the 
loosening periprosthetic tissue augments the inflammatory 
response to wear debris.4,18 VEGF is one of the most power-
ful angiogenic agents known.5 Saffar et al19 found that VEGF 
was expressed in all periprosthetic tissues, with intense VEGF 
staining found on both macrophages and multinucleated giant 
cells within the implant lining layer associated with the deposit 
of wear debris. Goodman et al18 reported recently that VEGF is 
overexpressed in periprosthetic tissues around loose implants, 
and demonstrated that the VEGF staining was colocalized with 
CD11b-positive macrophages. Furthermore, these authors 
found that the supernatants from titanium particle-challenged 
monocyte/macrophages significantly increased macrophage 
chemotactic activity, which could be inhibited by a neutral-
izing antibody against VEGF. We showed here that VEGF 
expression is significantly increased after UHMWPE particle 
PBS UHMWPE UHMWPE + VEGF    UHMWPE + R2/Fc    UHMWPE + SU5416
Flt-1
VEGF
A
Figure 2A Immunohistochemical detection of Flt-1 and VEGF in mice pouch membranes. (Original magnification × 200.) B, Implanted bone; M, pouch membrane. Positive 
staining was indicated by arrowhead
Abbreviations: RAnKL, Receptor activator of nuclear factor kappa B ligand;  TRAP, tartrate-resistant acid phosphatase;  VegF, vascular endothelial growth Factor;  PBs, 
phosphate-buffered saline; UhMWPe, ultra high-molecular weight polyethylene
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stimulation, suggesting that VEGF plays a critical role in the 
pathogenesis of aseptic loosening.
Multiple lines of evidence indicate that VEGF is 
critically involved in the initiation and persistence of 
inflammation.8,20–25 Although IL-1 and TNF are among the 
major cytokines detected in periprosthetic tissue,26 and are 
known to be potent mediators of bone resorption associ-
ated with aseptic loosening,27,28 the regulatory mechanisms 
of VEGF by these cytokines in the progression of aseptic 
  loosening are still unclear. We have shown that R2/Fc protein 
treatment suppresses UHMWPE particle-induced tissue 
inflammation and reduces the level of IL-1β and TNFα in 
UHMWPE-stimulated pouch tissues. Inhibition of inflam-
mation mediated by VEGF within the pouch tissue is an 
attractive approach to aseptic loosening treatment because it 
can prevent the formation of chronic inflammation provoked 
by wear debris in the periprosthetic tissue, especially at the 
early stage of aseptic loosening development. Relationships 
between VEGF activity and osteoclastogenesis have been 
reported. These include the stimulation of endothelial cells 
to produce receptor activation of nuclear factor κB (RANK), 
a critical protein in initiating osteoclastogenesis,29 the sharing 
of similar biological activity of macrophage colony-stimu-
lating factor30,31 in the support of osteoclastogenesis, and 
the stimulation of osteoclast recruitment,30 differentiation,32 
activation, and survival.9 The wear debris-induced increase 
of VEGF production reported previously,4,18 and found in 
this study, could exacerbate bone degradation that ultimately 
leads to the development of aseptic loosening after total joint 
replacement. Although R2/Fc treatment significantly dimin-
ished UHMWPE particle-induced inflammatory   osteolysis, 
the detailed cellular mechanisms of its effects are still 
unknown. We proposed that the therapeutic response of R2/Fc 
on inflammatory osteolysis acts mainly through inhibiting 
PBS
RANKL
TRAP
UHMWPE UHMWPE + VEGF UHMWPE + R2/Fc UHMWPE + SU5416 A
Figure 3A Therapeutic Effects of VEGF inhibitors on UHMWPE particles- induced inflammatory osteoclastogenesis. (A) Representative immunohistochemical staining of 
RANKL and histochemical TRAP staining in mice pouch membranes. (Original magnification × 200)  B, Implanted bone; M, pouch membrane.  Positive stained cells were 
indicated by arrowheads
Abbreviations: RAnKL, Receptor activator of nuclear factor kappa B ligand;  TRAP, tartrate-resistant acid phosphatase;  VegF, vascular endothelial growth Factor;  PBs, 
phosphate-buffered saline; UhMWPe, ultra high-molecular weight polyethylene
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recruitment of inflammatory cells (mainly macrophages) 
to inflamed tissues,18,33 macrophage activation,34 and 
osteoclastogenesis.29 Because other inflammatory cytokines, 
such as IL-1β and TNFα are known to be potent mediators 
of bone resorption associated with aseptic loosening,27,28 it 
may be more effective if anti-VEGF treatment is combined 
with other therapeutics, such as TNFα inhibitors. Although 
it is important to determine the precise mechanism of action, 
the significant suppression of UHMWPE particle-induced 
inflammatory osteolysis by R2/Fc is an attractive approach 
for this debilitating disease.
The receptors for VEGF belong to the tyrosine kinase 
receptor family, and two specific VEGF receptors have been 
identified to date, ie, VEGF receptor-1 (VEGFR-1; fms-like 
tyrosine kinase, Flt-1), and VEGFR-2 (Flk-1/KDR).7 VEGF 
appears to exert inflammatory effects through binding to its 
receptors, especially Flt-1. In addition to endothelial cells, 
Flt-1 is also expressed on cells of the monocyte-macrophage 
lineages and is involved in macrophage activation,33 
migration,35,36 and differentiation.9,30 The effectiveness of 
anti-Flt-1 antibody in collagen arthritis appears specific, 
because anti-Flk-1 antibody treatment proved ineffective,25 
and similar results were reported by De Bandt’s group in 
the transgenic K/BxN mouse RA model.21 The failure of 
anti-Flk-1 antibody to block arthritis suggests that suppres-
sion of inflammation (rather than angiogenesis) is primarily 
responsible for the clinical improvement. We have noticed 
a positive association between tissue inflammation and 
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Figure 4A Therapeutic effects of VEGF inhibitors on UHMWPE particle- induced inflammatory osteolysis. (microCT image analysis)  (A) Representative 3D isosurface analysis
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the levels of VEGF and Flt-1 gene transcripts in mouse 
pouch tissues containing UHMWPE particles.14 SU5416 
is a specific inhibitor of Flk-1 tyrosine kinase activity.37 
In this study, we found that SU5416 treatment has no sig-
nificant therapeutic effect on UHMWPE particle-induced 
tissue inflammation and osteoclastogenic bone resorption. 
In addition,   SU5416 shows little effect on inflammatory 
cytokine production and osteoclast formation. These data 
provide insight into the critical role of VEGF/Flt-1 signal-
ing in UHMWPE particle-induced inflammatory osteolysis, 
and may have important implications for the future treat-
ment of aseptic loosening conditions. It is obvious that 
VEGF/Flk-1 signaling plays little, if any, role in the pathogen-
esis of aseptic loosening development. Therefore, developing 
specific inhibitors targeted against VEGF/Flt-1 signaling 
will be promising in the prevention and treatment of aseptic 
loosening, especially in the early stages.
The interactive network of the VEGF/Flt-1 and 
RANKL/RANK pathways may play important roles in the 
initiation, progression, and resolution of aseptic loosening. 
Our data confirmed that R2/Fc treatment, through trapping 
VEGF in the milieu, inhibits UHMWPE particle-enhanced 
VEGF/Flt-1 signaling. As a result, a remarkable reduction of 
UHMWPE particle-induced pouch inflammatory osteolysis 
was observed. However, SU5416 treatment demonstrates 
no effects on UHMWPE particle-induced tissue damage. 
These data suggest that VEGF may be actively involved 
in the regulation of RANK/RANKL gene expression, and 
that it exerts a regulatory effect on the development of 
UHMWPE particle-induced inflammatory osteoclastogen-
esis through its unique Flt-1, rather than Flk-1, receptor 
located on monocyte/macrophage cell lineages. Taken 
together, our findings provide the biological rationale for a 
VEGF/Flt-1-targeted treatment strategy, especially in the early 
stages of wear debris-induced inflammatory response.
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